| Anxiety symptoms (label); pruritus; pre/postoperative sedation (label varies by product). View labelExact | Anxiety/acute distress (off label patterns vary): 25–50 mg every 6–8 hours as needed; consider 10–25 mg starting doses in older adults or high fall risk. | First-generation antihistamine (H1 antagonist) with sedating and anxiolytic effects; anticholinergic/antiemetic properties. | Hepatic | No | | - Sedation, falls, and driving impairment are often reassessed after initiation and during dose changes—especially in older adults.
- Anticholinergic effects (constipation, urinary retention, confusion) are commonly monitored; total anticholinergic burden is minimized when possible.
- QT risk: QT-prolonging co-medications and electrolytes are typically reviewed, and baseline ECGs are often considered when risk factors stack.
- If use becomes frequent, the diagnosis is often revisited and plans may shift toward long-term anxiety treatment rather than continued PRN escalation.
| No | 2025-12-28 |
|---|
| Anxiety disorders or short-term relief of anxiety symptoms (label). View labelExact | Start 7.5 mg twice daily (or 5 mg three times daily); increase by ~5 mg/day every 2–3 days as tolerated. | Non-benzodiazepine anxiolytic; 5-HT1A partial agonist (azapirone). | CYP3A4 | Single-dose range 2–3 h | No | — | - Follow-up within 2–4 weeks is commonly used to assess adherence, side effects, and whether anxiety symptoms are trending in the right direction.
- Dizziness and activation are commonly tracked during titration; slower titration can help if patients feel “wired” or unsteady.
- Interacting medications (CYP3A4 inhibitors/inducers) and food consistency (grapefruit) are worth reviewing when response changes.
- If no meaningful benefit after an adequate trial, stopping and switching or augmenting is common rather than continuing indefinitely.
| No | 2025-12-28 |
|---|
| Seizure disorders; panic disorder. View labelExact | Panic disorder (label): start 0.25 mg twice daily; increase every 3 days to 1 mg twice daily; maximum 4 mg/day. | Benzodiazepine; enhances GABA‑A receptor activity. | Hepatic | Steady-state mean 35 h | No | | - Sedation, cognition, gait/ataxia, and fall risk at each visit; counseling commonly covers driving and occupational safety after dose changes.
- Respiratory risk (sleep apnea, COPD) and co-prescribed CNS depressants; overdose education is important, and some settings coordinate naloxone when opioids are unavoidable.
- Misuse/diversion risk: PDMP review, documentation of indication/duration, and periodic reassessment with a time-limited plan are common.
- Withdrawal risk: written taper schedules, tracking rebound anxiety/insomnia, and slower tapers for long-term users or higher doses are typical.
| No | 2026-02-20 |
|---|
| Schizophrenia; acute manic/mixed episodes; bipolar depression; adjunct for major depressive disorder. View labelExact | Schizophrenia (IR): day 1 25 mg BID, titrate to 300–400 mg/day by day 4; maintenance 300–800 mg/day divided BID. | Antagonist at 5‑HT2A and D2 (transient), strong H1 and alpha‑1 activity. | CYP3A4 | Steady-state mean 6 h | No | | - Metabolic: weight/BMI, fasting glucose/HbA1c, and lipids (baseline and periodic).
- Sedation: assess next-day impairment and fall risk, especially with other sedatives.
| No | 2025-09-23 |
|---|